News / Taiwan / cnyes
Yi-Te's August Revenue Surges Over 1100% Year-on-Year
Health Technology · Biotechnology · cnyes · 2026-09-10
6461
Yi-Te (6461) reported a massive 1102.98% year-on-year revenue jump for August 2026, with the stock significantly outperforming the biotech sector recently.
What Happened
Revenue Performance: Yi-Te (6461) announced its revenue for August 2026 reached NT$5.65 million, marking a staggering 1102.98% increase compared to the same period last year. The company also recorded a month-on-month growth rate of 2579.62%, indicating a significant short-term surge in business activity.
Year-to-Date Results: Despite the impressive monthly figures, the cumulative revenue for the first eight months of 2026 stands at NT$42.31 million, representing a year-to-date decline of 56.2%. This suggests that the company's overall operational scale remains lower than the levels seen during the same period in the previous year.
Market Performance: The stock is currently trading at NT$24.3, having gained 54.65% over the past five trading days. This performance significantly outpaces the broader biotech sector index, which rose by only 1.01% during the same timeframe.
Company Background: Yi-Te operates within the biotechnology and medical sector, focusing on the research, development, manufacturing, and sales of pharmaceutical products. Investors are reminded that these figures are for informational purposes only and do not constitute investment advice.